Sinaptica Therapeutics will convene a scientific symposium on brain network dysfunction in Alzheimer's disease at the 19th Clinical Trials on Alzheimer's Disease conference in Boston on November 17, 2026. The session places circuit-level impairment, rather than amyloid and tau pathology alone, at the center of discussion on therapeutic targets. Network-based framing is increasingly relevant to efforts that aim to preserve cognitive function across the lifespan.
Key Points
- Sinaptica hosts CTAD symposium in Boston, November 17, 2026
- Focus is brain network dysfunction in Alzheimer's disease
- Circuit-level impairment examined alongside established amyloid and tau pathology
Longevity Analysis
Cognitive decline remains a principal determinant of healthspan, and attention to functional network integrity broadens the therapeutic landscape beyond protein-clearance strategies. Neuromodulation and circuit-targeted approaches offer a route to intervene on the systems that support memory and executive function, which matters for clinicians evaluating options for patients in early disease stages.
Original published by LT Wire.